|Bid||62.75 x 800|
|Ask||64.76 x 1400|
|Day's Range||63.89 - 64.59|
|52 Week Range||33.33 - 73.50|
|Beta (5Y Monthly)||-0.01|
|PE Ratio (TTM)||45.82|
|Forward Dividend & Yield||0.33 (0.51%)|
|Ex-Dividend Date||Jul 10, 2020|
|1y Target Est||68.31|
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration (USFDA).
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced a preclinical data presentation for E7777 (denileukin diftitox), its engineered IL-2-diphtheria toxin fusion protein, at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, being held virtually.
Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.